OmniAb, Inc. (OABI)Healthcare | Biotechnology | EmeryVille, United States | NasdaqGM
4.73 USD
+0.18
(3.956%)
⇧
(Oct. 15, 2026, 4 p.m.
EDT)
After hours: 4.75 +0.02 (0.423%) ⇧ (Oct. 15, 2026, 4:54 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 5:34 a.m. EDT
The investment case for OmniAb is severely compromised by a brutal multi-year price trajectory. Despite a 'strong buy' analyst recommendation and impressive gross margins, the stock has lost over 83% of its value over the last four years, with three consecutive years of negative annual returns. This persistent decline suggests the market views the current business fundamentals—specifically the negative operating cash flow and lack of profitability—as insufficient to sustain the current valuation, regardless of the high gross margins. The recent hiring of a COO and the 38% gain over the last six months are likely reactive to specific catalysts rather than a reversal of the long-term trend. With no dividend to provide income and a balance sheet showing negative free cash flow, there is no margin of safety here. The heavy put option activity confirms that retail and speculative capital are hedging against further downside, viewing the $2.50 level as a critical support zone. Until the company demonstrates sustained profitability or a clear path to positive operating cash flow, the structural damage to shareholder value remains too severe to ignore. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.594383 |
| AutoARIMA | 0.594384 |
| AutoTheta | 0.612403 |
| MSTL | 0.612587 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 26% |
| H-stat | 6.10 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.008 |
| Excess Kurtosis | -0.32 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 7.267 |
| Revenue per Share | 0.308 |
| Market Cap | 687,696,576 |
| Forward P/E | -16.17 |
| Beta | 1.37 |
| Profit Margins | -115.12% |
| Website | https://www.omniab.com |
As of Oct. 10, 2026, 5:34 a.m. EDT: Speculators are positioning defensively with heavy out-of-the-money put volume at the $2.50 strike across multiple expirations, creating a significant floor. This contrasts with relatively light call activity, which is concentrated near the money or further out, suggesting traders expect volatility but fear a drop to lower levels rather than a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.6764705 |
| Address1 | 5,980 Horton Street |
| Address2 | Suite 600 |
| All Time High | 10.5 |
| All Time Low | 1.22 |
| Ask | 2.54 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 1,342,410 |
| Average Daily Volume3 Month | 1,491,835 |
| Average Volume | 1,491,835 |
| Average Volume10Days | 1,342,410 |
| Beta | 1.372 |
| Bid | 1.52 |
| Bid Size | 2 |
| Board Risk | 10 |
| Book Value | 1.79 |
| City | EmeryVille |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.73 |
| Current Ratio | 4.798 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 4.755 |
| Day Low | 4.5306 |
| Debt To Equity | 7.267 |
| Display Name | OmniAb |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,793,361,600 |
| Earnings Call Timestamp Start | 1,793,361,600 |
| Earnings Timestamp | 1,793,363,400 |
| Earnings Timestamp End | 1,793,363,400 |
| Earnings Timestamp Start | 1,793,363,400 |
| Ebitda | -21,596,000 |
| Ebitda Margins | -0.56156 |
| Enterprise To Ebitda | -29.1 |
| Enterprise To Revenue | 16.341 |
| Enterprise Value | 628,444,288 |
| Eps Current Year | -0.366 |
| Eps Forward | -0.2925 |
| Eps Trailing Twelve Months | -0.35 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.2953 |
| Fifty Day Average Change | 0.4347 |
| Fifty Day Average Change Percent | 0.10120364 |
| Fifty Two Week Change Percent | 167.64705 |
| Fifty Two Week High | 5.43 |
| Fifty Two Week High Change | -0.6999998 |
| Fifty Two Week High Change Percent | -0.12891342 |
| Fifty Two Week Low | 1.3 |
| Fifty Two Week Low Change | 3.43 |
| Fifty Two Week Low Change Percent | 2.6384616 |
| Fifty Two Week Range | 1.3 - 5.43 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,633,008,600,000 |
| Float Shares | 118,244,557 |
| Forward Eps | -0.2925 |
| Forward P E | -16.17094 |
| Free Cashflow | -285,000 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 89 |
| Fullday Change | 0.19999981 |
| Fullday Change Percent | 4.3956 |
| Fullday Price | 4.75 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.98276 |
| Gross Profits | 37,794,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.15283 |
| Held Percent Institutions | 0.52801 |
| Implied Shares Outstanding | 145,390,398 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company offers animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. It has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California. |
| Long Name | OmniAb, Inc. |
| Market | us_market |
| Market Cap | 687,696,576 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_1765536061 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -44,270,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 696,420,006 |
| Number Of Analyst Opinions | 6 |
| Open | 4.6 |
| Operating Cashflow | -17,672,000 |
| Operating Margins | -0.49473998 |
| Overall Risk | 9 |
| Phone | 510 250 7800 |
| Post Market Change | 0.01999998 |
| Post Market Change Percent | 0.42283258 |
| Post Market Price | 4.75 |
| Post Market Time | 1,792,097,673 |
| Previous Close | 4.55 |
| Price Eps Current Year | -12.923497 |
| Price Hint | 4 |
| Price To Book | 2.6424582 |
| Price To Sales Trailing12 Months | 17.882221 |
| Profit Margins | -1.15116 |
| Quick Ratio | 4.53 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.17999983 |
| Regular Market Change Percent | 3.95604 |
| Regular Market Day High | 4.755 |
| Regular Market Day Low | 4.5306 |
| Regular Market Day Range | 4.5306 - 4.755 |
| Regular Market Open | 4.6 |
| Regular Market Previous Close | 4.55 |
| Regular Market Price | 4.73 |
| Regular Market Time | 1,792,094,400 |
| Regular Market Volume | 820,489 |
| Return On Assets | -0.08347 |
| Return On Equity | -0.16951 |
| Revenue Growth | 2.442 |
| Revenue Per Share | 0.308 |
| Sand P52 Week Change | 0.16440773 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 145,390,398 |
| Shares Percent Shares Out | 0.056399997 |
| Shares Short | 8,198,042 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 5,983,139 |
| Short Name | OmniAb, Inc. |
| Short Percent Of Float | 0.0619 |
| Short Ratio | 5.6 |
| Source Interval | 15 |
| State | CA |
| Symbol | OABI |
| Target High Price | 12.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 8.33333 |
| Target Median Price | 8.0 |
| Total Cash | 51,995,000 |
| Total Cash Per Share | 0.358 |
| Total Debt | 18,913,000 |
| Total Revenue | 38,457,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.35 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.52315 |
| Two Hundred Day Average Change | 2.20685 |
| Two Hundred Day Average Change Percent | 0.8746409 |
| Type Disp | Equity |
| Volume | 820,489 |
| Website | https://www.omniab.com |
| Zip | 94,608 |